Home » Psychology news » Allergan’s Rapastinel receives FDA breakthrough therapy designation for adjunctive treatment of Major Depressive Disorder
Allergan’s Rapastinel receives FDA breakthrough therapy designation for adjunctive treatment of Major Depressive Disorder
February 1, 2016 by NewsBot
Allergan plc., a leading global pharmaceutical company has announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S.
